Other News

Avinger Receives FDA Clearance of Next Generation Pantheris Device

REDWOOD CITY, Calif., May 23, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the Company received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its next generation Pantheris® Lumivascular atherectomy system, the first-ever image-guided atherectomy device for the treatment […]

Acarix appoints senior cardiovascular medtech marketing expert as member of the Board of Directors

Malmö, May 23, 2018 Acarix appoints senior cardiovascular medtech marketing expert as member of the Board of Directors Acarix, developer of the CADScor®System for Coronary Artery Disease (CAD) risk assessment, today announced the appointment of a highly experienced marketing expert, Johanne Louise Brændgaard, as a member of the board of directors. “We are delighted to […]

Acarix AB recruits Per Persson as Chief Commercial Officer

Malmö, May 23, 2018 Acarix AB recruits Per Persson as Chief Commercial Officer  Acarix AB (publ) (“Acarix”), today announced the recruitment of Per Persson as new Chief Commercial Officer to accelerate the sales execution for the CADScor®System for Coronary Artery Disease (CAD) risk assessment. He has a solid background in sales and marketing of medical […]

New Medtronic Data Show Significant Blood Pressure Lowering Effect of Renal Denervation in Patients Taking Anti-Hypertensive Medication

DUBLIN and PARIS – May 23, 2018 – Medtronic plc (NYSE:MDT) today announced first-ever-data from the SPYRAL HTN-ON MED Study. Initial study results found statistically significant and clinically important blood pressure reductions in hypertensive patients prescribed anti-hypertension medications treated with the Symplicity Spyral renal denervation (RDN) system with no major adverse safety events out to six […]

Fantom’s Positive Two-Year Results Show Sustained Safety and Efficacy

SAN DIEGO, May 23, 2018 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, reported sustained safety and efficacy of the Fantom®bioresorbable scaffold (“BRS”) through two years based on data from the FANTOM II trial presented today at the EuroPCR conference in Paris, France. […]

Berlin Cures Announces Formation of Scientific Advisory Board

ZUG, Switzerland, May 23, 2018 /PRNewswire/ — Drug developer Berlin Cures today announced the formation of a Scientific Advisory Board (SAB) and the appointment of its first two members, Prof. Beda M. Stadler and Prof. Wilhelm Vetter, to help advance the clinical development of BC 007, the first drug designed to target the autoimmune cause of heart failure as well as the symptoms of […]

Amaranth Presented Interim Nine-Month Follow-up MAGNITUDE (98 micron) and Two-Year Follow-up APTITUDE (115 micron) Data at EuroPCR Symposium

MOUNTAIN VIEW, CA , May 23, 2018 (GLOBE NEWSWIRE) — Amaranth Medical, a medical device company developing next-generation bioresorbable scaffolds for the interventional cardiology market, provided an update on the company’s sirolimus-eluting bioresorbable scaffold (BRS) products during a satellite symposium during EuroPCR 2018, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions. The symposium, […]

Abbott’s Investigational Tendyne™ Device for Mitral Valve Replacement Demonstrates Positive Outcomes at 30 Days in Global Study

PARIS, May 23, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system, the first and only mitral replacement valve that is repositionable and fully retrievable to allow for more precise implantation, helping improve patient outcomes. The trial is […]

Newest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease

ABBOTT PARK, Ill., May 23, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for XIENCE SierraTM, the newest generation of the company’s gold-standard XIENCE everolimus-eluting coronary stent system. XIENCE stents are among the world’s most-used and studied stents and have an exceptional safety record with low rates of […]

ReCor Medical Announces RADIANCE-HTN SOLO Hypertension Study Meets Primary Efficacy Endpoint, Pivotal Study Submission, and New Principal Investigator

ReCor Medical announced today that the RADIANCE-HTN SOLO study met its primary efficacy endpoint and demonstrated a statistically significant reduction in blood pressure in hypertensive patients. In addition, the company announced submission of an IDE supplement to the US FDA for a pivotal study of its Paradise System for the treatment of hypertension, and that Prof. Ajay Kirtane […]